miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell Lymphoma
T. Fuertes, E. Alvarez-Corrales, P. Ubieto-Capella…·V. G. de Yebenes
This paper investigates the combination of miR-28 and ibrutinib as a therapy for DLBCL, showing enhanced anti-tumor effects and a new gene signature for prognosis.